AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
imipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| substances of the imipramine group | 1427 | 50-49-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
| 0.10 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 5.09 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 42 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 12 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 13 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.08 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 16 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK | 51 | |||
| kinase-selectivity-class | AXL,PDK4,SIK2,STK33,TTK | 5 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.735 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 | |
| rat-kpuu-brain | Rat brain Kpuu | 0.533 | % | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 16, 1959 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 124.59 | 18.44 | 77 | 3756 | 144981 | 90479633 |
| Paranoia | 71.23 | 18.44 | 25 | 3808 | 12883 | 90611731 |
| Toxicity to various agents | 70.42 | 18.44 | 73 | 3760 | 287773 | 90336841 |
| Hallucination, auditory | 66.03 | 18.44 | 25 | 3808 | 15950 | 90608664 |
| Antidepressant drug level above therapeutic | 58.05 | 18.44 | 11 | 3822 | 479 | 90624135 |
| Psychotic disorder | 52.88 | 18.44 | 26 | 3807 | 31204 | 90593410 |
| Stress cardiomyopathy | 34.78 | 18.44 | 15 | 3818 | 13340 | 90611274 |
| Skin hyperpigmentation | 32.99 | 18.44 | 12 | 3821 | 6839 | 90617775 |
| Procedural hypotension | 30.26 | 18.44 | 8 | 3825 | 1592 | 90623022 |
| Sleep apnoea syndrome | 27.53 | 18.44 | 17 | 3816 | 31730 | 90592884 |
| Iris hyperpigmentation | 26.61 | 18.44 | 4 | 3829 | 41 | 90624573 |
| Cardio-respiratory arrest | 25.02 | 18.44 | 21 | 3812 | 63119 | 90561495 |
| Depressed level of consciousness | 24.39 | 18.44 | 22 | 3811 | 72762 | 90551852 |
| Respiratory arrest | 24.31 | 18.44 | 16 | 3817 | 33295 | 90591319 |
| Decreased activity | 23.98 | 18.44 | 10 | 3823 | 8182 | 90616432 |
| Urinary hesitation | 22.56 | 18.44 | 7 | 3826 | 2456 | 90622158 |
| Limb mass | 20.09 | 18.44 | 7 | 3826 | 3521 | 90621093 |
| Catatonia | 19.80 | 18.44 | 8 | 3825 | 6048 | 90618566 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 56.73 | 24.09 | 62 | 1989 | 229074 | 42390210 |
| Blepharospasm | 55.82 | 24.09 | 13 | 2038 | 1355 | 42617929 |
| Completed suicide | 53.28 | 24.09 | 41 | 2010 | 96424 | 42522860 |
| Long QT syndrome | 44.99 | 24.09 | 13 | 2038 | 3154 | 42616130 |
| Neuroleptic malignant syndrome | 43.38 | 24.09 | 21 | 2030 | 21451 | 42597833 |
| Pyelitis | 40.80 | 24.09 | 7 | 2044 | 151 | 42619133 |
| Muscle rigidity | 37.71 | 24.09 | 16 | 2035 | 12043 | 42607241 |
| Trismus | 37.27 | 24.09 | 11 | 2040 | 2873 | 42616411 |
| Dystonia | 36.80 | 24.09 | 16 | 2035 | 12774 | 42606510 |
| Delusion | 25.56 | 24.09 | 13 | 2038 | 14721 | 42604563 |
| Overdose | 25.07 | 24.09 | 28 | 2023 | 105236 | 42514048 |
| Cognitive disorder | 24.41 | 24.09 | 17 | 2034 | 34155 | 42585129 |
| Brain oedema | 24.30 | 24.09 | 13 | 2038 | 16314 | 42602970 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 153.86 | 18.28 | 111 | 5097 | 242270 | 110341821 |
| Toxicity to various agents | 93.77 | 18.28 | 114 | 5094 | 480441 | 110103650 |
| Paranoia | 64.96 | 18.28 | 28 | 5180 | 22346 | 110561745 |
| Neuroleptic malignant syndrome | 62.49 | 18.28 | 31 | 5177 | 34028 | 110550063 |
| Hallucination, auditory | 54.35 | 18.28 | 26 | 5182 | 26371 | 110557720 |
| Antidepressant drug level above therapeutic | 52.10 | 18.28 | 11 | 5197 | 746 | 110583345 |
| Overdose | 46.29 | 18.28 | 56 | 5152 | 233738 | 110350353 |
| Psychotic disorder | 40.82 | 18.28 | 27 | 5181 | 50910 | 110533181 |
| Long QT syndrome | 34.90 | 18.28 | 13 | 5195 | 7105 | 110576986 |
| Pyelitis | 33.98 | 18.28 | 7 | 5201 | 421 | 110583670 |
| Stress cardiomyopathy | 30.81 | 18.28 | 15 | 5193 | 15791 | 110568300 |
| Procedural hypotension | 30.14 | 18.28 | 9 | 5199 | 2496 | 110581595 |
| Dystonia | 29.09 | 18.28 | 17 | 5191 | 25788 | 110558303 |
| Trismus | 28.56 | 18.28 | 11 | 5197 | 6585 | 110577506 |
| Electrocardiogram QT prolonged | 26.41 | 18.28 | 29 | 5179 | 108931 | 110475160 |
| Drug interaction | 25.73 | 18.28 | 66 | 5142 | 500117 | 110083974 |
| Respiratory depression | 25.72 | 18.28 | 17 | 5191 | 31984 | 110552107 |
| Skin hyperpigmentation | 25.62 | 18.28 | 11 | 5197 | 8685 | 110575406 |
| Cardio-respiratory arrest | 24.96 | 18.28 | 29 | 5179 | 115807 | 110468284 |
| Muscle rigidity | 24.92 | 18.28 | 15 | 5193 | 24016 | 110560075 |
| Electrocardiogram abnormal | 22.89 | 18.28 | 13 | 5195 | 18696 | 110565395 |
| Withdrawal syndrome | 21.26 | 18.28 | 15 | 5193 | 31365 | 110552726 |
| Parkinsonism | 20.83 | 18.28 | 13 | 5195 | 22174 | 110561917 |
| Decreased activity | 20.15 | 18.28 | 10 | 5198 | 10964 | 110573127 |
| Speech disorder | 19.64 | 18.28 | 19 | 5189 | 61550 | 110522541 |
| Iris hyperpigmentation | 19.61 | 18.28 | 3 | 5205 | 31 | 110584060 |
| Suicide attempt | 19.19 | 18.28 | 24 | 5184 | 103370 | 110480721 |
| Waxy flexibility | 18.60 | 18.28 | 4 | 5204 | 296 | 110583795 |
| Limb mass | 18.55 | 18.28 | 7 | 5201 | 3962 | 110580129 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06AA02 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors |
| MeSH PA | D000928 | Antidepressive Agents |
| MeSH PA | D000929 | Antidepressive Agents, Tricyclic |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018759 | Adrenergic Uptake Inhibitors |
| MeSH PA | D049990 | Membrane Transport Modulators |
| CHEBI has role | CHEBI:35469 | antidepressant |
| FDA EPC | N0000175752 | Tricyclic Antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35640 | adrenergic uptake inhibitor |
| CHEBI has role | CHEBI:76779 | EC 3.4.21.26 (prolyl oligopeptidase) inhibitor |
Related Drugs by ATC class:
N06AA Non-selective monoamine reuptake inhibitors 20 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Nocturnal enuresis | indication | 8009008 | |
| Depressive disorder | indication | 35489007 | |
| Neuralgia | off-label use | 16269008 | |
| Cataplexy | off-label use | 46263000 | |
| Anxiety | off-label use | 48694002 | |
| Narcolepsy | off-label use | 60380001 | DOID:8986 |
| Bulimia nervosa | off-label use | 78004001 | |
| Neuropathic pain | off-label use | 247398009 | |
| Panic disorder | off-label use | 371631005 | DOID:594 |
| Attention deficit hyperactivity disorder | off-label use | 406506008 | |
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Suicidal thoughts | contraindication | 6471006 | |
| Alcoholism | contraindication | 7200002 | |
| Bipolar disorder | contraindication | 13746004 | DOID:3312 |
| Electroconvulsive therapy | contraindication | 23835007 | |
| Alcohol intoxication | contraindication | 25702006 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Schizophrenia | contraindication | 58214004 | DOID:5419 |
| Intestinal obstruction | contraindication | 81060008 | DOID:8437 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Seizure disorder | contraindication | 128613002 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Mania | contraindication | 231494001 | |
| Hypomania | contraindication | 231496004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Syncope | contraindication | 271594007 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Surgical procedure | contraindication | 387713003 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Myocardial infarction in recovery phase | contraindication | 418044006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.04 | Basic |
| pKa2 | 5.01 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | Kd | 7.43 | WOMBAT-PK | CHEMBL | |||
| Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Kd | 8.85 | WOMBAT-PK | CHEMBL | |||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.28 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.24 | PDSP | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.83 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.80 | WOMBAT-PK | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 7.50 | WOMBAT-PK | |||||
| Alpha-2B adrenergic receptor | GPCR | IC50 | 7.10 | WOMBAT-PK | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.41 | WOMBAT-PK | |||||
| Histamine H1 receptor | GPCR | IC50 | 7.61 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.38 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.08 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.22 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.95 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.08 | WOMBAT-PK | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.07 | PDSP | |||||
| Adenosine receptor A3 | GPCR | IC50 | 8.36 | CHEMBL | |||||
| Voltage-dependent N-type calcium channel subunit alpha-1B | Ion channel | IC50 | 4.66 | CHEMBL | |||||
| Major prion protein | Surface antigen | EC50 | 5 | CHEMBL | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 4.77 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 1 | Ion channel | BLOCKER | IC50 | 5.70 | IUPHAR | ||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 5.22 | WOMBAT-PK | |||||
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.44 | CHEMBL | |||||
| Sphingomyelin phosphodiesterase | Enzyme | IC50 | 5.30 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.90 | WOMBAT-PK | |||||
| D(2) dopamine receptor | GPCR | Ki | 6.17 | WOMBAT-PK | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 8.77 | CHEMBL | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 7.38 | CHEMBL | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.46 | CHEMBL | |||||
| Transporter | Transporter | Ki | 7.92 | CHEMBL | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 7.38 | CHEMBL | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 7.92 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.80 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 6.14 | CHEMBL | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 8.30 | CHEMBL | |||||
| Histamine H1 receptor | GPCR | IC50 | 10.22 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | IC50 | 6.52 | CHEMBL | |||||
| Pleiotropic ABC efflux transporter of multiple drugs | Transporter | IC50 | 4.66 | CHEMBL | |||||
| Glutamate NMDA receptor | Ion channel | IC50 | 4.85 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | Ki | 7.19 | CHEMBL | |||||
| Serotonin (5-HT) receptor | GPCR | IC50 | 7.36 | CHEMBL | |||||
| Adrenergic receptor alpha-2 | GPCR | Ki | 6.59 | CHEMBL | |||||
| Dopamine receptor | GPCR | IC50 | 6.19 | CHEMBL | |||||
| Adrenergic receptor alpha-1 | GPCR | Ki | 7.34 | CHEMBL | |||||
| Serotonin 2 (5-HT2) receptor | GPCR | Ki | 7.64 | CHEMBL | |||||
| G protein-activated inward rectifier potassium channel 4 | Ion channel | BLOCKER | EC50 | 4.50 | IUPHAR | ||||
| G protein-activated inward rectifier potassium channel 2 | Ion channel | BLOCKER | IC50 | 4.30 | IUPHAR | ||||
| Sigma intracellular receptor 2 | Membrane receptor | Ki | 5.68 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019785 | VUID |
| N0000147875 | NUI |
| D00815 | KEGG_DRUG |
| 73-07-4 | SECONDARY_CAS_RN |
| 113-52-0 | SECONDARY_CAS_RN |
| 10075-24-8 | SECONDARY_CAS_RN |
| 4017862 | VANDF |
| 4017863 | VANDF |
| 4019785 | VANDF |
| C0020934 | UMLSCUI |
| CHEBI:47499 | CHEBI |
| IXX | PDB_CHEM_ID |
| CHEMBL11 | ChEMBL_ID |
| CHEMBL2105257 | ChEMBL_ID |
| DB00458 | DRUGBANK_ID |
| CHEMBL1692 | ChEMBL_ID |
| CHEMBL3989845 | ChEMBL_ID |
| D007099 | MESH_DESCRIPTOR_UI |
| 3696 | PUBCHEM_CID |
| 357 | IUPHAR_LIGAND_ID |
| 793 | INN_ID |
| OGG85SX4E4 | UNII |
| 150816 | RXNORM |
| 2328 | MMSL |
| 4870 | MMSL |
| 4871 | MMSL |
| 81685 | MMSL |
| d00259 | MMSL |
| 001498 | NDDF |
| 001499 | NDDF |
| 001500 | NDDF |
| 3378009 | SNOMEDCT_US |
| 36113004 | SNOMEDCT_US |
| 372718005 | SNOMEDCT_US |
| 4203009 | SNOMEDCT_US |
| 1916 | INN_ID |
| OGG85SX4E4 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Imipramine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0273 | CAPSULE | 75 mg | ORAL | ANDA | 20 sections |
| Imipramine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0274 | CAPSULE | 100 mg | ORAL | ANDA | 20 sections |
| Imipramine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0275 | CAPSULE | 125 mg | ORAL | ANDA | 20 sections |
| Imipramine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0276 | CAPSULE | 150 mg | ORAL | ANDA | 20 sections |
| IMIPRAMINE PAMOATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-963 | CAPSULE | 75 mg | ORAL | NDA | 22 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0035 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 21 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3148 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50436-2022 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 21 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-1344 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-2221 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-2571 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64125-133 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 24 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64125-134 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 24 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64125-135 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 24 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-169 | TABLET | 10 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-170 | TABLET | 25 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-171 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67046-1564 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 19 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-3669 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2768 | TABLET | 10 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-311 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-312 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-313 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 20 sections |
| Imipramine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-314 | CAPSULE | 75 mg | ORAL | ANDA | 20 sections |
| Imipramine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-315 | CAPSULE | 100 mg | ORAL | ANDA | 20 sections |
| Imipramine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-316 | CAPSULE | 125 mg | ORAL | ANDA | 20 sections |
| Imipramine Pamoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-317 | CAPSULE | 150 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69315-133 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69315-134 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 20 sections |
| Imipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69315-135 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 20 sections |